Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Pishvaian MJ, Slack R, Koh EY, Beumer JH, Hartley ML, Cotarla I, Deeken J, He AR, Hwang J, Malik S, Firozvi K, Liu M, Elston B, Strychor S, Egorin MJ, Marshall JL. Pishvaian MJ, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2012 Dec;70(6):843-53. doi: 10.1007/s00280-012-1969-9. Epub 2012 Sep 27. Cancer Chemother Pharmacol. 2012. PMID: 23014737 Free PMC article. Clinical Trial.
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W Sr, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Bose P, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2012 Jun;69(6):1657-67. doi: 10.1007/s00280-012-1839-5. Epub 2012 Feb 15. Cancer Chemother Pharmacol. 2012. PMID: 22349810 Free PMC article. Clinical Trial.
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ. Beumer JH, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2008 Jul;62(2):363-8. doi: 10.1007/s00280-007-0603-8. Epub 2007 Sep 26. Cancer Chemother Pharmacol. 2008. PMID: 17899082 Clinical Trial.
Effect of antacid on imatinib absorption.
Sparano BA, Egorin MJ, Parise RA, Walters J, Komazec KA, Redner RL, Beumer JH. Sparano BA, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2009 Feb;63(3):525-8. doi: 10.1007/s00280-008-0778-7. Epub 2008 May 24. Cancer Chemother Pharmacol. 2009. PMID: 18500518 Free PMC article. Clinical Trial.
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ, Friedman HS. Reardon DA, et al. Among authors: egorin mj. Cancer. 2009 May 15;115(10):2188-98. doi: 10.1002/cncr.24213. Cancer. 2009. PMID: 19248046 Free PMC article. Clinical Trial.
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
Egorin MJ, Shah DD, Christner SM, Yerk MA, Komazec KA, Appleman LR, Redner RL, Miller BM, Beumer JH. Egorin MJ, et al. Br J Clin Pharmacol. 2009 Sep;68(3):370-4. doi: 10.1111/j.1365-2125.2009.03466.x. Br J Clin Pharmacol. 2009. PMID: 19740393 Free PMC article. Clinical Trial.
Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.
Tawbi HA, Tran AL, Christner SM, Lin Y, Johnson M, Mowrey E, Appleman LR, Stoller R, Miller BM, Egorin MJ, Beumer JH. Tawbi HA, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2013 Nov;72(5):1143-7. doi: 10.1007/s00280-013-2283-x. Epub 2013 Sep 14. Cancer Chemother Pharmacol. 2013. PMID: 24036846 Free PMC article. Clinical Trial.
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC. Ramanathan RK, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2005 Apr;55(4):354-360. doi: 10.1007/s00280-004-0909-8. Epub 2004 Oct 27. Cancer Chemother Pharmacol. 2005. PMID: 15723261 Clinical Trial.
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC. Krishnamurthi SS, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2009 Feb;63(3):441-50. doi: 10.1007/s00280-008-0754-2. Epub 2008 Apr 15. Cancer Chemother Pharmacol. 2009. PMID: 18414865 Free PMC article. Clinical Trial.
349 results